Pomerantz Law Firm Initiates Class Action Against Savara Inc. Over Securities Violations

Pomerantz Law Firm Takes Action Against Savara Inc.

On October 23, 2025, Pomerantz LLP, a well-known law firm specializing in corporate and securities litigation, announced the filing of a class action lawsuit against Savara Inc., a clinical-stage biopharmaceutical company, along with a number of its top officials. The class action is based in the United States District Court for the Eastern District of Pennsylvania, under the docket number 25-cv-05147.

Background of the Case

The lawsuit represents a class consisting of individuals and entities that purchased or acquired Savara securities between March 7, 2024, to May 23, 2025. The plaintiffs are seeking to recover damages for alleged violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5.

As per the announcements, participants who bought Savara securities during the specified period have until November 7, 2025, to apply to be appointed as a Lead Plaintiff for the class action. Further details of the complaint can be accessed through Pomerantz's official website.

Core Allegations Against Savara

Savara Inc. is focused on developing treatments for rare respiratory diseases, with its lead product candidate, MOLBREEVI (also known as molgramostim), undergoing a pivotal Phase 3 clinical trial for treating autoimmune pulmonary alveolar proteinosis (aPAP). The lawsuit claims that throughout the class period, Savara and its officials made materially false and misleading statements regarding the company’s operations and business prospects.

Specifically, the defendants are accused of failing to disclose that:
1. The MOLBREEVI Biologics License Application (BLA) lacked crucial information concerning the product's chemistry and manufacturing processes.
2. Regulatory approval for the BLA from the FDA was, therefore, unlikely in its existing form.
3. There would likely be delays in the submission timeline for the BLA.

These misrepresentations allegedly misled investors regarding the company's financial health and capital sufficiency leading up to 2026 and beyond. This ultimately prompted questions about whether Savara would need to seek additional capital.

Recent Developments

The situation escalated when Savara released a press statement on May 27, 2025, stating that the FDA had delivered a refusal to file letter concerning the MOLBREEVI BLA. The FDA indicated that the application was not sufficiently complete for a substantive review, requiring further data about Chemistry, Manufacturing, and Controls (CMC). This led market analysts, including Guggenheim, to downgrade their price targets for Savara, forecasting significant financial challenges for the company moving forward.

In light of these developments, Savara's share price plummeted by 31.69%, closing at $1.94 per share on the same day, which alarmed many investors. Further upsetting the company's communications, on August 13, 2025, Savara had to announce that it planned to resubmit the BLA later than previously communicated, now aiming for December 2025 instead of the anticipated timeline.

Conclusion

Pomerantz LLP has a strong history of fighting for the rights of investors, having overseen numerous high-profile corporate litigations throughout its decades of operation. As the situation evolves, investors of Savara Inc. will be keenly watching how the class action against the company unfolds, particularly with regard to the implications for their investments and the future of MOLBREEVI as a potential treatment option for aPAP.

For any investors affected by these developments, further information and assistance can be sought by contacting Danielle Peyton at Pomerantz LLP directly.